Pilot trial of paclitaxel-trastuzumab adjuvant therapy for early stage breast cancer: a trial of the ECOG-ACRIN cancer research group (E2198)

BACKGROUND: Blockade of human epidermal growth factor receptor type 2 (HER2) has dramatically improved outcome for patients with HER2-positive breast cancer. Trastuzumab, an anti-HER2 monoclonal antibody, has previously demonstrated improvement in overall survival (OS) in patients with metastatic an...

Descripción completa

Detalles Bibliográficos
Autores principales: Schneider, Bryan P, O'Neill, Anne, Shen, Fei, Sledge, George W, Thor, Ann D, Kahanic, Stephen P, Zander, Paul J, Davidson, Nancy E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4701997/
https://www.ncbi.nlm.nih.gov/pubmed/26625004
http://dx.doi.org/10.1038/bjc.2015.405

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4701997/
https://www.ncbi.nlm.nih.gov/pubmed/26625004
http://dx.doi.org/10.1038/bjc.2015.405

Ejemplares similares